Tekmira Pharmaceuticals has filed a 10-Q – Quarterly report [Sections 13 or 15(d)] with the U.S. Securities and Exchange Commission (Filing, 10-Q, Tekmira Pharmaceuticals, MAY 6, 2015, View Source [SID1234503673]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On May 6, 2015 CEL-SCI Corporation (NYSE MKT: CVM) reported that it has commenced an underwritten public offering of $35.0 million of its common stock (Press release, Cel-Sci, MAY 6, 2015, View Source [SID:1234506573]). CEL-SCI intends to grant the underwriter a 30-day option to purchase up to an additional $5.25 million of its common stock. FBR Capital Markets & Co. is acting as sole book-running manager for the offering.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

CEL-SCI intends to use the net proceeds from the offering primarily to complete patient enrollment in its Phase 3 clinical trial of Multikine (Leukocyte Interleukin, Injection) as a neoadjuvant therapy for patients with squamous cell carcinoma of the head and neck, to fund the Phase 1 trial of Multikine in HIV/HPV co-infected patients with anal warts, to repay a $1.1 million note upon maturity in July 2015 and for general corporate purposes.

The offering will be made by CEL-SCI pursuant to a shelf registration statement on Form S-3 declared effective by the Securities and Exchange Commission ("SEC") on July 8, 2014. A preliminary prospectus supplement and accompanying prospectus related to the offering have been filed with the SEC and are available on the SEC’s website located at View Source Copies of the preliminary prospectus supplement and accompanying prospectus relating to the offering may be obtained from FBR Capital Markets & Co., Attention: Syndicate Prospectus Department, 1300 North 17th Street, Arlington, Virginia 22209, Telephone: 703-312-9500, Email: [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such state or other jurisdiction.

On May 6, 2015 Kymab ,a leading monoclonal antibody biopharmaceutical company reported that US$50 million is being invested by Woodford Patient Capital Trust plc (LSE:WPCT,"Woodford") and Malin Corporation plc (ISE:MLC, "Malin") (Press release, Kymab, MAY 6, 2015, View Source [SID1234537013]). The additional investment follows the first US$40 million Series B investment from the Wellcome Trust and the Bill & Melinda Gates Foundation to complete a US$90 million Series B financing.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The funds will enable Kymab to maximize the potential of its Kymouse platform and advance its proprietary pipeline of first-in-class therapeutic human monoclonal antibodies in areas of significant unmet medical need.

In association with the financing, Kymab has added two pre-eminent life science executives to the Board. G. Kelly Martin, former CEO of Elan Corporation, plc, and Director of Malin; and, Dr. Adrian Howd, CEO of Malin.

"We believe Kymab has one of the most comprehensive humanised transgenic antibody platforms underpinned by strong intellectual property," explained Adrian Howd, CEO of Malin. "We are pleased to invest in a world leading antibody company."

Kymab is using the Kymouse transgenic human antibody platform to discover and develop fully human monoclonal antibody drugs. Recent data published in Nature Biotechnology demonstrate that the KymouseTM technology yields an antibody library constituted from 100 trillion different antibodies. From this deep library rare high-quality antibodies can be selected and developed into therapeutics.

"We are delighted to welcome high quality investors of the calibre of Malin and Woodford to Kymab which support our goal to build Kymab into a sustainable biopharmaceutical company," said David Chiswell, Chairman and interim CEO of Kymab. "The funds will be used to maximise the potential of the Kymab pipeline as we develop and commercialise monoclonal antibody medicines for difficult and novel drug targets."

"Kymab has assembled a talented leadership team; an efficient and effective discovery platform with broad application demonstrated by the pipeline of product opportunities already established," commented Kelly Martin, Director of Malin. "We look forward to working with David and his team to fully realize the potential of the Company’s programs, initially in immune-oncology and immunology, and the broader technology platform."

Antibodies are one of the best-selling classes of drugs today; five of the top ten best selling drugs are antibodies. This is because antibodies are natural products with exquisite specificity and potency, and generally have superior safety profiles. The challenge has been to capture the full human antibody repertoire and to recapitulate all its attributes.

ArQule has filed a 10-Q – Quarterly report [Sections 13 or 15(d)] with the U.S. Securities and Exchange Commission (Filing, 10-Q, ArQule, MAY 6, 2015, View Source [SID1234503622]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Abbott has filed a 10-Q – Quarterly report [Sections 13 or 15(d)] with the U.S. Securities and Exchange Commission (Filing, 10-Q, Abbott, MAY 6, 2015, View Source [SID1234503674]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!